# Peptides for Injury Recovery: Building the Right Stack

Most healing peptide guides stop at BPC-157 and TB-500. That covers two early bottlenecks, blood flow and repair-cell movement, while ignoring the cellular energy those repair cells spend. More complex injuries can also stall on chronic inflammation, poor collagen quality, disrupted sleep, and hormonal timing.

The tiered framework here organizes compounds by function: a soft-tissue starter stack, escalation layers for refractory cases, and separate routes for cartilage, bone, nerve, CNS, and conditioning problems. It works as a diagnostic sequence rather than a longer ingredient list, identifying what is stalling the repair and then addressing that bottleneck specifically.

[Jump to protocol →](#protocol-dosing-timing-and-schedules)

---

## At a Glance

| | |
| --- | --- |
| **Soft-tissue starter** | [BPC-157](/content/bpc-157) + [TB-500](/content/tb-500) + [NAD+](/content/nad-guide) — addresses blood flow, repair-cell movement, and cellular energy. |
| **Refractory soft tissue** | [KPV](/content/kpv) enters when inflammation keeps cycling; [GHK-Cu](/content/ghk-cu-skin) when collagen quality is the limiter. |
| **Injury-specific routes** | [ARA-290](/content/ara-290) (peripheral nerve), [VIP](/content/vasoactive-intestinal-peptide) (disc/spine context), cartilage/bone/CNS-specific stacks when the tissue is not ordinary soft tissue. |
| **Support layers** | [SS-31](/content/ss-31) (stalled healing), [Selank](/content/selank) (stress), [DSIP](/content/dsip) (sleep), [Tesamorelin](/content/tesamorelin)/[Sermorelin](/content/sermorelin) (GH recovery) — added if needed. |
| **Protocol duration** | BPC-157 and TB-500 each run 4–6 weeks, then stop and assess. Support layers cycle on their own schedules. |
| **Results timeline** | Reduced pain and improved mobility within 1–2 weeks, structural remodeling from week 2 onward, with the course assessed at 4–6 weeks. |
| **Key caveat** | No controlled trial has tested any of these combinations. Individual compounds have preclinical support; the stacking rationale is mechanistic, not clinical. |

The evidence is uneven. BPC-157 has 36 studies in a 2025 systematic review — 35 preclinical, 1 clinical with 12 patients.¹ TB-4 (thymosin beta-4, the parent molecule most research uses) has roughly 50 preclinical studies and Phase 1 human safety data. No controlled trial has tested any multi-peptide combination, so every stacking protocol described here rests on mechanistic rationale and uncontrolled observation. TB-4 trial data also does not transfer to a TB-500 vial: different molecule, different mass.

BPC-157 came off FDA Category 2 on 22 April 2026 by nominator withdrawal rather than because a safety concern was resolved. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding it to the 503A Bulks List, against FDA's own staff, who had recommended against listing, and reached the same result separately for TB-500 and KPV. Operative status is recommended for listing, pending FDA action.

That is an access-pathway question, not therapeutic approval and not a scientific verdict. A committee recommendation is not a rule; notice-and-comment rulemaking follows and can take over a year, and compounding still constitutes unapproved new drug manufacturing under the FD&C Act. The evaluation covered ulcerative colitis only, with tendonitis excluded for insufficient nomination information. For tested athletes, BPC-157 and TB-500 remain prohibited under WADA rules.

---

## Why Injuries Stall: Repair Bottlenecks

An injury that doesn't improve after 4–6 weeks isn't just "slow healing." Something specific is blocking the repair process. Five core bottlenecks explain most soft-tissue stalls. Sleep, growth-hormone timing, and mitochondrial stability are later escalation layers, not automatic starter-stack problems.

#### 1. Poor perfusion — the tissue is starved

Damaged tissue needs blood flow to deliver oxygen, nutrients, and immune cells. When circulation is restricted, which is common in tendons, ligaments, and avascular joint surfaces, repair stalls at the earliest stage.

Signs: the area stays cold or pale, swelling persists weeks post-injury, improvements from physical therapy don't hold between sessions. [BPC-157](/content/bpc-157) signals new blood vessel formation (angiogenesis¹) and helps reopen the circulation the injury response shut down.

#### 2. Cell migration — the repair crew can't organize

Blood flow gets supplies to the area, but repair cells still need to move through the damaged tissue and organize into useful structure. When that migration step is weak, the injury feels less cold but still locked, stiff, or glued down.

Signs: range of motion improves briefly then stalls, fascia feels stuck, stiffness drops slower than pain, or the injury feels alive but not rebuilt. [TB-500](/content/tb-500) is the migration-side bet: it supports the cell-movement side of repair while BPC-157 supports blood flow and local repair tone.²

#### 3. Cellular energy failure — repair cells can't do the work

Tissue repair is metabolically expensive. Repair cells, immune cells, and blood vessel cells all require functional mitochondria producing adequate energy. In damaged tissue, mitochondria are often compromised by oxidative stress.

Signs: healing that starts but plateaus; recurrent setbacks with modest activity; fatigue concentrated around the injury site. [NAD+](/content/nad-guide) restores the cellular energy pool. [SS-31](/content/ss-31) is a later layer when the issue is mitochondrial membrane stress and repeated flare after loading.⁴

#### 4. Poor collagen quality — rebuilding with weak material

New tissue forms, but it lacks structural integrity. Collagen fibers are disorganized, cross-linking is insufficient, and the repair tissue doesn't tolerate load. Common in connective tissue injuries where collagen architecture determines function.

Signs: repeated re-injury at the same site, tissue that feels "loose" or unstable, gains that reverse under load. [GHK-Cu](/content/ghk-cu-skin) regulates collagen remodeling enzymes, directing repair toward organized functional tissue rather than scar.⁵

#### 5. Inflammation gating — the switch won't turn off

Some injuries get blood flow and repair cells back online, then keep cycling: better after a session, worse two days later, swelling after moderate activity. The repair program never consolidates because the inflammation switch keeps re-opening.

Signs: recurring swelling after activity, persistent warmth, pain that worsens with rest rather than load. [KPV](/content/kpv) helps keep the inflammation switch from staying on (NF-kB pathway³) without the tissue-weakening tradeoff of corticosteroids.

#### Later layer: poor sleep quality — the repair window never opens

Growth hormone peaks during deep sleep, driving overnight tissue repair. When sleep architecture is disrupted by fragmented sleep, insufficient deep sleep stages, or difficulty falling asleep during recovery, the primary repair window stays closed.

Signs: waking unrefreshed, difficulty reaching or maintaining deep sleep, recovery that stalls despite good daytime compliance with rehab and nutrition. [DSIP](/content/dsip) restores deep sleep architecture directly. [Selank](/content/selank) addresses the stress and anxiety that fragment sleep in the first place.

#### Later layer: hormonal mis-timing — recovery signals fire at the wrong time

Even with adequate sleep, growth hormone release can be blunted — cortisol stays elevated through the night, GH pulses are weak or mistimed, and the overnight repair signal never reaches full amplitude.

Signs: slow healing despite decent sleep, compounding fatigue that doesn't match activity level, poor recovery response to rehab. GH secretagogues like [tesamorelin](/content/tesamorelin) or [sermorelin](/content/sermorelin) restore pulsatile GH release.⁶

These bottlenecks frequently overlap. A tendon injury with poor blood supply often develops chronic inflammation because inadequate circulation prevents immune cell clearance. The starter stack covers blood flow, repair-cell movement, and energy; refractory cases add collagen-quality and inflammation-gating layers.

---

## The Peptide Toolkit: Building the Protocol

### Step 1 — the core stack

The core stack is the protocol's entry point for ordinary soft-tissue injury: tendon, ligament, muscle, fascia, joint capsule, scar remodeling, or post-procedure tissue support. These three compounds cover blood flow, repair-cell movement, and energy. The BPC-157 + TB-500 pairing is the foundation of the [Wolverine Stack](/content/wolverine-stack); NAD+ keeps the repair work funded.

| Compound | Role |
| --- | --- |
| [BPC-157](/content/bpc-157) | Drives repair at the injury site — builds new blood vessels, activates the cells that lay down new tissue, and makes the injury site more responsive to growth hormone.¹ |
| [TB-500](/content/tb-500) | The migration-side bet. It is the synthetic thymosin beta-4 fragment, not the full parent peptide, and appears to work after metabolic clipping into a shorter repair-active signal. |
| [NAD+](/content/nad-guide) | Supplies the cellular energy every repair process runs on. Damaged tissue has compromised mitochondria — NAD+ keeps the energy pipeline open so the other compounds can do their work. |

#### Oral alternative to BPC-157

PDA — same 15-amino-acid sequence, stabilized with an arginate salt for oral bioavailability.⁸ PDA at 500–1000 mcg/day stands in for injectable BPC-157 where injections are off the table. Trade-off: oral delivery is systemic rather than local, so the concentrated signaling near the injury site is lost.

### Step 2 — matching the injury type

Beyond the starter stack, the protocol adds only what matches the bottleneck:

- **Connective tissue / collagen quality** — add [GHK-Cu](/content/ghk-cu-skin). Regulates collagen turnover and cross-linking — directs repair toward organized functional tissue instead of scar. The signal for it is unstable tissue or re-injury at the same site.⁵
- **Inflammation cycling** — add [KPV](/content/kpv). Helps keep the inflammation switch from staying on. The signal for it is swelling that returns after activity or an injury that keeps oscillating instead of consolidating.³
- **Disc / spinal degeneration** — add [VIP](/content/vasoactive-intestinal-peptide). Only peptide with direct disc data — slowed degeneration and improved disc cushioning material in a mouse model.⁹ Short half-life (~1 min IV), so frequent dosing matters.
- **Nerve pain / neuropathy** — add [ARA-290](/content/ara-290). Activates the innate repair receptor — reduced pain and regenerated small nerve fibers in Phase 2 human trials.¹⁰ Systemic injection, doesn't need to be near the nerve.

### Step 3 — support layers when needed

These address bottlenecks that emerge during recovery, not upfront:

- **Healing stalled after 4+ weeks on core** — add [SS-31](/content/ss-31). Stabilizes mitochondrial membranes against oxidative damage that accumulates during prolonged repair.⁴
- **High stress during recovery** — add [Selank](/content/selank). Reduces anxiety with immune-modulating properties. Breaks the stress → cortisol → impaired healing cycle without sedation.
- **Poor sleep quality** — add [DSIP](/content/dsip). Restores deep sleep architecture — the phase where GH-driven repair happens.
- **Weak GH response / slow overnight recovery** — add [Tesamorelin](/content/tesamorelin) or [Sermorelin](/content/sermorelin). Restores pulsatile GH release. Complementary to DSIP — DSIP opens the window, secretagogues amplify the signal. The convention is before bed on an empty stomach, cycled 8–12 weeks on, 4 weeks off.

For cartilage-specific interest, Cartalax is a short bioregulatory peptide (Ala-Glu-Asp) studied in Russian literature for cartilage matrix preservation — it may slow cartilage breakdown in lab models, but has no injury recovery data and limited availability outside specialty suppliers.²³

---

## Protocol: Dosing, Timing, and Schedules

### Core stack

| Compound | Dose | Route |
| --- | --- | --- |
| BPC-157 | 250–500 mcg daily | SubQ near injury site |
| TB-500 | 1–2.5 mg 2–3×/week | SubQ near injury site when safe |
| NAD+ | 50–200 mg about 3×/week | IM preferred; SubQ 50–100 mg per dose, split into injections of 50 mg or less |

BPC-157 and TB-500 each run 4–6 weeks, then stop and assess. Neither has a taper or maintenance phase in the derived position. BPC-157 starts at 250 mcg, with a locked weekly total of 1.25–3.5 mg and locked course totals at the low end of 5.0 mg over four weeks and 7.5 mg over six. Those totals sit below seven-day-a-week arithmetic on a 250 mcg dose, so they describe the low end of real dosing frequency rather than an unbroken daily course.

For TB-500 the locked values are 1–2.5 mg per dose, two to three times weekly, against a 4–6 mg weekly target inside a full envelope of 2.0–7.5 mg, with 2–3 mg per week as a conservative first cycle.

Inject near the injury site when it is easy and safe. For hard-to-reach locations, abdominal or ordinary SubQ rotation is the practical alternative. BPC-157 and TB-500 can share a syringe on TB-500 days. NAD+ is separate. If KPV is added for tier-2 inflammation cycling, it can share with BPC-157; GHK-Cu should be separate.

The basis for near-injury placement is the human dosing record rather than a local depot. Every human cohort ever given BPC-157 received it into or onto the target tissue: intra-articular into the knee, intravesical into the bladder wall, rectal enema onto colonic mucosa. The only systemic exposure on record is a two-person intravenous safety pilot with no indication and no efficacy endpoint. Two limits travel with that: no human study has used the subcutaneous route, and no study in any species has compared near-injury against distal injection.²⁶

#### TB-500 dosing structure

The derived position is 1–2.5 mg per dose, two to three times weekly, for 4–6 weeks, targeting 4–6 mg per week.¹¹ There is no loading phase and no maintenance step: the weekly amount is the same in week one as in week five. Above 6 mg/week exceeds both anchors the band rests on, which makes it a deliberate exception rather than a default.

Those anchors are veterinary and they disagree by 2.6x. An equine protocol scales to 2.29 mg/week for a 70 kg human, and back-calculation from a 5 mg greyhound dose gives 5.91 mg/week. No human efficacy endpoint anchors the band. Pulsed milligram dosing fits the short-cycle migration-signal model rather than a measured human pharmacokinetic schedule.

A dose of 2–4 mg belongs to full-length thymosin beta-4, not to the TB-500 fragment. Where a protocol prints 2–4 mg as TB-500's dose, it has merged the parent into the fragment, and TB-4 trial data does not transfer to a TB-500 vial: different molecule, different mass. Which one is in the vial reads off the Certificate of Analysis (molecular weight ~859 Da for the fragment, ~4,900 Da for full TB-4). Full-length TB-4 can access pathways the fragment cannot, including Ac-SDKP anti-fibrotic biology. See the [TB-500 guide](/content/tb-500) for details.

Near-injury placement is worth the small effort for TB-500, on a different argument than BPC-157's. The fragment carries a small positive charge patch, and tendon, cartilage and disc are built on strongly negatively charged matrix, so the working hypothesis is that it is drawn in and held rather than washed out. That predicts a clean test which nobody has run: matched near-injury and distal dosing should differ in tissue retention. Reconstitute to the smallest practical volume. This is a hypothesis about matrix binding, not an established mechanism, and not a claim that the fragment seeks out injury.

Calculate your exact injection volumes with the [peptide dosing calculator](/tools/calculator).

### Situational compounds

| Compound | Dose | Route | Timing | Injury Type |
| --- | --- | --- | --- | --- |
| [KPV](/content/kpv) | 200–500 mcg | SubQ | Daily | Inflammation cycling |
| [GHK-Cu](/content/ghk-cu-skin) | 1–1.5 mg | SubQ | 3×/week | Connective tissue, collagen quality |
| [VIP](/content/vasoactive-intestinal-peptide) | 100–200 mcg | SubQ | Daily (can split into 2 doses) | Disc, spinal degeneration |
| [ARA-290](/content/ara-290) | 2–4 mg | SubQ, abdomen | Daily | Nerve pain, neuropathy |

Keep GHK-Cu in a separate syringe. ARA-290 is injected systemically — its nerve-protective effects don't require proximity to the nerve injury.¹⁰ VIP's ~1-minute IV half-life means subQ dosing provides brief systemic exposure; splitting the daily dose into two injections extends coverage.

### Optional support compounds

| Compound | Dose | Route | Timing |
| --- | --- | --- | --- |
| [SS-31](/content/ss-31) | 6 mg | SubQ | Daily through week 8, then daily or 2–3×/week |
| [Selank](/content/selank) | 250–500 mcg | SubQ or intranasal | Morning or before rehab |
| [DSIP](/content/dsip) | 100–300 mcg | SubQ | Before bed |
| [Tesamorelin](/content/tesamorelin) | 1–2 mg | SubQ | Before bed, empty stomach |
| [Sermorelin](/content/sermorelin) | 200–500 mcg | SubQ | Before bed, empty stomach |

#### SS-31

Targets the mitochondria directly — it stabilizes the inner membrane that produces cellular energy (cardiolipin binding⁴). NAD+ provides the fuel; SS-31 protects the engine. Its place in the protocol is healing that stalls after 4+ weeks on the core stack, the pattern that points to mitochondrial exhaustion NAD+ alone isn't resolving.⁴

#### Selank

Can be injected subQ or taken intranasally. Intranasal bypasses liver processing and provides more direct brain access, which may give it an edge for stress and anxiety specifically.

#### Sleep and GH recovery

DSIP and GH secretagogues (tesamorelin, sermorelin) work on related but distinct problems. DSIP extends the deep sleep window — the phase where GH-driven repair happens. Secretagogues amplify the GH signal within that window. They're complementary, not redundant. GH secretagogues are dosed before bed on an empty stomach (90+ minutes after eating) and cycled 8–12 weeks on, 4 weeks off.

---

## Injury-Specific Protocol Adjustments

### Tendon, ligament, and fascia

The strongest preclinical case for peptide-assisted healing.²¹ BPC-157 promotes tendon repair cell outgrowth and stimulates cell migration (FAK-paxillin signaling¹³). Rat Achilles tendon studies show accelerated healing with improved biomechanical strength.¹ TB-4-treated Achilles tendons showed uniform fiber bundles with increased collagen fibril diameter versus controls.¹⁴

#### Protocol

Core stack injected near the injury site. [GHK-Cu](/content/ghk-cu-skin) joins it when collagen quality is the bottleneck (tissue feels unstable, re-injury at the same site). Collagen peptide supplementation (5–15 g/day, 30–45 min before tendon-loading exercise) is a well-supported adjunct.¹⁵

#### Plantar fasciitis

No direct peptide data. Plantar fascia is structurally similar to tendon, with dense type I collagen and minimal vascularity, and shares the same wear-and-tear degeneration pattern. Same mechanisms are biologically plausible but unvalidated for plantar fascia specifically.

### Joint and cartilage

Joint capsule, ligament, and soft-tissue irritation can use the soft-tissue ladder. Focal cartilage defects are different: cartilage is avascular, slow, and matrix-limited. Those cases route toward a cartilage-specific stack where GHK-Cu is a stronger matrix lever and intra-articular BPC-157 is clinician-only, not an at-home translation. The knee case series identified 17 patients and analysed 16, reporting 87.5% overall improvement and 91.6% for BPC-157 alone; 7 of 12 (58%) held beyond six months on telephone follow-up.⁷ Intra-articular dosing there was 4 mg as a single clinician-performed administration.

#### GH secretagogues and joint injuries: a monitoring caution

GH can cause mild joint swelling as a side effect — in joints with existing inflammation, cartilage degradation, or impingement, that additional fluid and tissue growth can worsen symptoms rather than help. Where tesamorelin or sermorelin is layered in for overnight recovery, increased joint stiffness or swelling in the first 2 weeks is the signal to watch, and worsening impingement is the signal to stop. Ligament-driven injuries tolerate GH secretagogues better than cartilage or joint surface injuries.

Worth tracking: a 2025 Stanford study showed that blocking the enzyme 15-PGDH in aged mice regenerated articular cartilage — increasing smooth-cartilage-producing cells from 22% to 42%.¹⁶ Small molecule approach, not a peptide, but the most rigorous cartilage regeneration advance in the field. Phase 1 safety trials are underway.

### Shoulder and rotator cuff

Core stack. BPC-157 at 10 mcg/kg produced total functional recovery in a rat rotator cuff model — full range of motion restored.¹⁷

#### GH secretagogues for shoulder: negative results

The only human RCT testing GH on rotator cuff repair (Oh 2018, n=76) found no significant improvement.¹⁸ A separate preclinical study found GH worsened force-to-failure at the tendon-bone interface.¹⁸ Where GH secretagogues are run for general recovery, increased shoulder stiffness or impingement is the signal to watch — the same joint swelling side effect applies here.

For frozen shoulder, relaxin-2 reverses joint capsule scarring in mouse models but remains preclinical.

### Disc, spine, and back

Ordinary back strain, fascia, or capsule irritation runs on the soft-tissue ladder. Disc, nerve, and CNS presentations route differently. BPC-157 has animal spinal-cord-injury data, but that does not make the soft-tissue stack a CNS protocol.¹⁹ TB-4 reduced nerve cell loss and scar tissue formation in separate models.²⁰

For disc degeneration, the protocol layers in [VIP](/content/vasoactive-intestinal-peptide) — the only peptide with direct disc data.⁹ For neuropathic pain from nerve compression, the protocol adds [ARA-290](/content/ara-290).

SS-31 has separate relevance for disc injuries — it reduced inflammation-induced cell death in disc cells by scavenging mitochondrial oxidative stress.¹² For chronic discogenic pain, biomolecular therapies including peptide-based approaches are an active research area, though clinical translation remains early.²⁴

No human RCTs exist for peptides in disc herniation or back pain. The spinal cord injury data involves severe acute trauma models — extrapolation to chronic disc degeneration is mechanistic, not validated. BPC-157 has not been directly tested on herniated discs in any model.

### Post-surgical recovery

Core stack. The protocol opens 48–72 hours post-operatively, which lets initial clotting and the acute inflammatory response settle before repair signaling enters. BPC-157 is injected near the surgical site at a flat 250–500 mcg daily for 4–6 weeks, then stopped for assessment. The loading-then-maintenance phase structure that field sources describe for this window is not the derived position: neither compound steps its dose across the course.¹¹

BPC-157 can counteract corticosteroid-impaired healing in preclinical models, suggesting compatibility with post-surgical steroid protocols.¹

### Chronic and old injuries

Core stack plus [GHK-Cu](/content/ghk-cu-skin), with adjusted expectations. Chronic injuries have established scar tissue, adapted blood supply patterns, and often mitochondrial depletion. The BPC-157 and TB-500 course still runs 4–6 weeks and then stops for assessment; a chronic presentation does not extend it, because no dose-response curve exists to support the longer exposure. [SS-31](/content/ss-31) joins when the core stack produces initial improvement that plateaus.

---

## Timeline: What to Expect

| Timeframe | What's Happening |
| --- | --- |
| **Days 1–7** | BPC-157 initiates new blood vessel formation. Injury site may feel warmer as circulation returns. NAD+ supports the energy cost of early repair. |
| **Weeks 1–2** | Most people notice reduced pain and improved mobility. TB-500 pulsed dosing supports the migration side of the repair process. |
| **Weeks 2–4** | Active tissue remodeling. New collagen deposition begins. Range of motion and load tolerance improve. |
| **Weeks 4–6** | Structural maturation. Collagen fibers organize under mechanical load. Physical therapy and progressive loading compound the peptide effects. This is where the BPC-157 and TB-500 course ends and the injury is assessed off-protocol. |
| **After the course** | A stall at assessment turns the lens to collagen quality, sleep, or hormonal timing bottlenecks. Support layers such as GH secretagogues run their own 8–12 week cycles independently of the core stack. |

---

## Supporting Factors

Peptides provide biological repair signals. The raw materials for actual tissue construction come from nutrition and mechanical loading.

#### Collagen peptide supplementation

5–15 g/day, taken 30–45 minutes before tendon-loading exercise or physical therapy. Vitamin C (500–1000 mg, taken with collagen) is a required cofactor for collagen cross-linking. Glycine (3–5 g/day) provides the most abundant amino acid in collagen structure.¹⁵

#### Progressive mechanical loading

Non-negotiable. Collagen fibers align along lines of mechanical stress. Without controlled loading, new tissue forms as disorganized scar. Peptides and rehab are synergistic — neither replaces the other.

#### Sleep

GH secretion peaks during deep sleep. [DSIP](/content/dsip) and GH secretagogues address this pharmacologically, but basic sleep hygiene remains the foundation.

---

## FAQ

**Protocol Basics**

### What role does NAD+ play in injury-recovery protocols?

[NAD+](/content/nad-guide) isn't a healing compound — it's the energy currency that fuels every repair process in the protocol. Repair cells, immune cells, and blood vessel cells all require functional mitochondria producing adequate energy. In damaged tissue, mitochondrial function is often compromised by oxidative stress.

Injectable NAD+ at 50–200 mg IM about 3×/week keeps the metabolic pipeline open so BPC-157 and TB-500 can execute their signaling. SubQ runs 50–100 mg per dose, split into injections of 50 mg or less if IM is not workable, and still stings more than IM; above 100 mg use IM. Oral precursors (NR or NMN, 250–1000 mg/day) are legitimate for steady support or avoiding injections. The protocol runs without NAD+ entirely, but that asks repair cells to work overtime on a depleted energy budget.

### What outcomes are associated with BPC-157 used without the full stack?

BPC-157 alone has the strongest individual evidence base for tissue repair among the compounds in this protocol.¹ Reported improvement from BPC-157 on its own is common, particularly for localized injuries, though it comes from uncontrolled observation rather than a trial endpoint.

The fuller stack addresses more bottlenecks at once: TB-500 adds the migration-side bet, NAD+ covers energy, KPV covers inflammation cycling, and GHK-Cu covers collagen quality. BPC-157 alone is still a reasonable starting point for mild-to-moderate injuries where chronic inflammation isn't the primary issue.

### What is the typical cycle length for a BPC-157 + TB-500 injury protocol?

4–6 weeks for both compounds, then stop and assess.

BPC-157 runs 250–500 mcg once daily throughout, starting at 250. TB-500 runs 1–2.5 mg two to three times weekly across the same 4–6 weeks, with no taper step. The reassessment happens off-protocol at the end of the course rather than at a mid-course checkpoint.

The chronic-versus-acute split does not extend the BPC-157 course. Twelve weeks at 500 mcg daily is a 42 mg course, nothing in the evidence supports the top of that range, and no dose-response curve was ever established for the compound. GH secretagogues cycle separately on their own schedule: 8–12 weeks on, 4 weeks off.

### How is a healing plateau after four weeks evaluated?

A stall reopens the bottleneck framework. With the starter stack already covering blood flow, migration, and energy, the next question is what is still limiting the tissue, and each answer maps to a compound: collagen quality maps to [GHK-Cu](/content/ghk-cu-skin); inflammation cycling to [KPV](/content/kpv); poor sleep to [DSIP](/content/dsip); overnight consolidation failure to a GH secretagogue.

When none of those fit, [SS-31](/content/ss-31) is the lever for mitochondrial membrane instability that NAD+ alone didn't resolve. Extending the same protocol unchanged rarely produces a different result.

### Which peptides are studied for inflammation control?

[KPV](/content/kpv) is the standout. It turns off the inflammation switch (NF-kB³) without the tissue-weakening effects of corticosteroids or the repair-signal suppression of NSAIDs.

BPC-157 has secondary anti-inflammatory properties but isn't primarily an anti-inflammatory compound. For gut-related inflammation, oral KPV acts directly on intestinal tissue via a gut nutrient transporter (PepT1). For injury-specific inflammation, subcutaneous KPV near the injury site provides concentrated local effect.

### How is non-response evaluated when an injury does not improve with the protocol?

First is the bottleneck itself. The most common reason protocols underperform isn't the wrong compounds — it's the wrong diagnosis of what's stalling healing.

Second are the non-peptide fundamentals: progressive mechanical loading, collagen supplementation, sleep quality, nutrition. Their absence limits the protocol's effectiveness.

Third, initial improvement that plateaued is a specific signal — the one that points to SS-31 for mitochondrial support or GHK-Cu for collagen remodeling. Nothing moving after 4 weeks with proper rehabilitation is the line past peptides: the injury may need imaging or intervention they can't replace, which is a physician's call.

**Safety and Regulatory**

### Are any of these peptides FDA approved?

No. None of the peptides in this protocol have FDA approval for injury recovery.

BPC-157 came off Category 2 on 22 April 2026 by nominator withdrawal. On 23 July 2026 the Pharmacy Compounding Advisory Committee voted to recommend adding it to the 503A Bulks List against FDA's own staff recommendation, reaching the same result separately for TB-500 and KPV.

Operative status is recommended for listing, pending FDA action, and the evaluation covered ulcerative colitis only. That affects access and compounding; it is not approval for injury recovery. [SS-31](/content/ss-31) (elamipretide) is FDA-approved as Forzinity for Barth syndrome, but that label does not translate into injury-recovery approval. [ARA-290](/content/ara-290) completed Phase 2 trials for sarcoidosis neuropathy but development stalled.

The absence of FDA approval reflects patent economics. BPC-157 is a fragment of a naturally occurring gastric protein — it cannot be patented as a novel compound, which means no company can recoup the $1–2 billion cost of full approval. The same economic barrier applies to most peptides derived from endogenous human sequences. Regulatory status tells you about commercial viability, not about safety or efficacy.

### Is BPC-157 safe? Is TB-500 safe? Are there side effects?

**BPC-157:** Repeat-dose animal exposure ran 28 days plus a 14-day recovery period, and no lethal or acutely toxic dose was identified across roughly a 3,300x range (6 mcg/kg to 20 mg/kg).¹ The envelope is broad but not clean, and two findings should not be smoothed over.

Clotting time moved reversibly in opposite directions in the two species tested: rat male aPTT shortened about 10% at 1 and 4 mg/kg, dog male aPTT lengthened 20–25%. A shortened aPTT is a venous-thromboembolism risk factor and a prolonged one a bleeding risk factor, so direction matters clinically, and no human coagulation data exists by any route. A female-rat cluster also turned up at the lowest dose tested (0.2 mg/kg: ALT +24%, glucose +31%, TG +87%). Study authors called these incidental; FDA declined that reading for the liver cluster.

Human side effects reported remain mild: occasional injection-site irritation, GI upset with oral dosing. The limit worth stating precisely is that the human record is uncontrolled and the single controlled read was underpowered. No repeat-dose animal study has run past 28 days plus recovery.

**TB-500/TB-4:** Phase I human safety data exists for recombinant TB-4 — 84 healthy volunteers (54 single-dose, 30 multiple-dose) tolerated doses up to 25 μg/kg daily for 10 days with no serious adverse events.²⁵ The synthetic TB-500 and TB-4 sold by peptide suppliers differ from the recombinant version used in this trial, and their safety profiles have not been independently characterized.

**KPV:** Tripeptide fragment of alpha-MSH, a naturally occurring hormone. No adverse events in published research, but no formal human safety studies exist either.

Short-term data is reassuring within a 28-day repeat-dose window and says nothing past it.

### Do BPC-157 and TB-500 cause cancer?

No evidence of tumor promotion exists for either compound.

BPC-157's blood-vessel-forming properties raise a theoretical concern — tumors need blood supply, and a compound that promotes capillary formation could theoretically support that. However, preclinical data suggests BPC-157 may inhibit certain tumor growth pathways.²² TB-4 research has found both pro- and anti-tumorigenic associations in different tissue contexts.

Active cancer or a recent cancer history is the standard precautionary contraindication for blood-vessel-forming compounds. For people without cancer history, the theoretical risk appears low, but long-term human studies that would definitively resolve this don't exist.

### How is concurrent NSAID or ibuprofen use evaluated with BPC-157, TB-500, and KPV?

It's possible, but it may blunt the protocol's effectiveness. NSAIDs suppress inflammatory signaling that BPC-157 and TB-500 modulate as part of the repair process. Suppressing inflammation pharmacologically while supporting it with peptides creates competing signals.

KPV works differently — it turns off the inflammation switch (NF-kB) to resolve chronic inflammation without suppressing repair signals. Running KPV alongside NSAIDs is less contradictory, but redundant.

For pain management during the protocol, the lower-conflict pattern is NSAIDs used sparingly at the lowest effective dose rather than daily. Corticosteroids present a stronger concern — they directly impair collagen quality.

### What are the contraindications?

Active cancer or history of cancer — BPC-157's blood-vessel-forming properties are theoretically concerning for tumor blood supply. No evidence of tumor promotion exists, and preclinical data suggests BPC-157 may inhibit certain tumor growth pathways,²² but the theoretical concern warrants caution.

Pregnancy and lactation: insufficient safety data. Autoimmune conditions: the immune-modulating peptides ([KPV](/content/kpv), TB-500, [Selank](/content/selank)) may alter immune balance unpredictably.

**Pharmacokinetics**

### How long do BPC-157 and TB-500 remain in the body?

BPC-157 clears in approximately 15 minutes (IV/IM studies in rats and dogs — no formal human subQ data exists). But plasma clearance doesn't equal effect duration. BPC-157 triggers gene expression cascades that persist for weeks to months after the compound clears.¹⁹ The peptide delivers instructions; the biological response continues independently.

TB-4 has the better human data: Phase I studies in 84 healthy volunteers showed a dose-dependent half-life of 0.5–2.1 hours after IV administration.²⁵ Caveat: these studies used recombinant human thymosin beta-4, not the synthetic TB-500 fragment or synthetic TB-4 via subQ — the pharmacokinetics may differ.

### How long do KPV and VIP remain in the body?

KPV has no published half-life data in any species. As an unmodified tripeptide, it likely clears within minutes. Anti-inflammatory effects persist longer because the inflammation switch (NF-kB) stays off after the peptide clears.

[VIP](/content/vasoactive-intestinal-peptide) has well-established human pharmacokinetics: approximately 1-minute half-life after IV administration. SubQ absorption is slower than IV, which provides somewhat longer exposure per dose. Splitting the daily dose into two injections extends coverage further. The disc degeneration research used local delivery models, but community protocols use systemic subQ at 100–200 mcg/day.⁹

### How long do NAD+ and SS-31 remain in the body?

Injectable [NAD+](/content/nad-guide) supports the metabolic pool through extracellular breakdown into usable precursors plus acute signaling. IM is the preferred at-home route for active rebuilds; SubQ runs 50–100 mg per dose, split into injections of 50 mg or less, and stings more than IM. Oral precursors (NMN, NR) are legitimate steady-support options rather than fake substitutes.

[SS-31](/content/ss-31) (elamipretide) has the best pharmacokinetic data of any compound in this protocol — Phase I through III human trials. SPISC-101 directly administered 6 mg SubQ daily for seven days to healthy adults and measured parent and metabolite PK. Peak plasma occurs in 1–2 hours, with a parent half-life of roughly 2–4 hours.²⁷

### How long does ARA-290 remain in the body?

Approximately 20 minutes half-life after subQ injection (human data from multiple clinical trials). Despite the short plasma presence, biological effects persist far longer — activation of the innate repair receptor triggers downstream gene expression lasting hours. This is why dosing is once daily despite 20-minute clearance.¹⁰

**Administration**

### Which injection sites are used for BPC-157, TB-500, and KPV?

Near the injury site when it is easy and safe to reach. For hard-to-reach locations (spine, deep hip), abdominal injection is the practical alternative.

The reason is the shape of the human record rather than a local depot. Every human cohort ever dosed with BPC-157 received it into or onto the target: intra-articular into the knee, intravesical into the bladder wall, rectal enema onto colonic mucosa. The only systemic exposure in the human ledger is a two-person intravenous safety pilot with no indication and no efficacy endpoint.²⁶

Two limits belong with that. No human study has used the subcutaneous route at all, and nobody has compared near-injury against distal injection in any species, so near-injury subq follows the direction of the human evidence without being proven by it. A rat distribution finding, skeletal muscle below plasma an hour after IM dosing, rules out a lasting subq depot; that is narrower than where to deliver, and it is one timepoint in uninjured rodent tissue.

Separately, and about concentration rather than location: reconstitute on the dilute side. The marketed 2,000 mcg/mL strength is roughly 1,000x the concentration at which the only fine-grained concentration-response curve for this peptide reverses direction.

BPC-157, TB-500, and KPV are chemically compatible — draw all three into the same syringe on TB-500 days if KPV is part of the protocol. On non-TB-500 days, BPC-157 + KPV can share one injection. GHK-Cu and NAD+ stay separate.

### Which injection sites are used for ARA-290 and VIP?

[ARA-290](/content/ara-290): subcutaneous, typically abdominal. The sarcoidosis neuropathy trials used systemic delivery, not local injection. Its neuroprotective effects don't require proximity to the nerve injury.¹⁰

[VIP](/content/vasoactive-intestinal-peptide): subcutaneous, 100–200 mcg daily. The ~1-minute IV half-life is short, so splitting into two doses (morning and evening) extends coverage. SubQ absorption is slower than IV, which helps. The disc degeneration research used local delivery models, but community protocols use systemic subQ.

### What role does SS-31 play in injury recovery, and when is it considered?

[SS-31](/content/ss-31) protects mitochondrial membranes. NAD+ provides the fuel; SS-31 protects the machinery that burns it.⁴

It's not a first-line compound. Its place is healing that stalls after 4+ weeks on the core stack — the pattern that suggests mitochondrial exhaustion NAD+ alone isn't resolving. For chronic injuries with long-standing tissue damage, the case is stronger from the start.

For a mild acute injury responding to the core stack, SS-31 is unnecessary. For a chronic injury that has resisted other interventions, it addresses a bottleneck that nothing else in the protocol targets.

### Is there a difference between oral BPC-157 (PDA) and the injectable version?

Same 15-amino-acid sequence, different delivery. PDA stabilizes BPC-157 with an arginate salt for oral bioavailability.⁸ Injectable near the injury site concentrates the compound locally. Oral PDA distributes systemically — lower concentration at any specific site, broader coverage overall.

For localized injuries, injectable is preferred. For systemic inflammation, gut healing, or avoiding injections entirely, oral PDA at 500–1000 mcg/day is the alternative. Both are sometimes run together.

### Is there a difference between oral and injectable KPV?

Yes. Oral KPV reaches intestinal tissue directly via a gut nutrient transporter (PepT1) — specifically effective for gut inflammation. Injectable KPV (subQ) provides systemic anti-inflammatory coverage including at injury sites.

For injury-specific inflammation, subcutaneous KPV is the default. Oral KPV is mainly a gut-local tool and makes the most sense when the formulation is protected, enteric, or carrier-style.

### How do intranasal and injectable Selank differ in this protocol?

Both work. SubQ injection is the default in this protocol, since the other compounds are already injected. Intranasal bypasses liver processing and provides more direct brain access, which is where [Selank's](/content/selank) anxiety-reducing effects are most relevant — so intranasal may have an edge for stress and anxiety specifically.

**Compatibility**

### What is known about combining this protocol with GLP-1-based weight-loss therapy?

No direct interaction data exists. They target entirely different receptor systems.

The practical concern is metabolic context. GLP-1 therapy produces significant caloric deficit and muscle mass reduction. Tissue repair is metabolically expensive. Running an aggressive recovery protocol during aggressive caloric restriction may limit healing capacity.

Running both at once, the levers that matter most are protein intake (1.6–2.2 g/kg/day minimum), collagen peptide supplementation, and a caloric deficit kept shallow enough not to starve the repair process.

### How are peptide protocols and physical therapy used together?

The two are designed to run together. Peptides provide biological repair signals. Physical therapy provides mechanical loading signals. Collagen fibers align along lines of stress; without controlled loading, new tissue forms as disorganized scar.

The combination is synergistic — neither replaces the other. The timing convention puts collagen peptide supplementation (5–15 g with vitamin C) 30–45 minutes before PT sessions.¹⁵

### What secondary effects are reported with this protocol?

The compounds don't limit their effects to one injury site. Improved skin quality, faster healing at unrelated sites, and reduced GI symptoms are the secondary effects reported for BPC-157, all from uncontrolled clinical observation rather than measured endpoints.¹ [GHK-Cu](/content/ghk-cu-skin) improves skin elasticity and wound healing beyond the target injury.⁵ NAD+ has broad metabolic effects beyond the injury site.

**Injury-Specific**

### Which protocol components are used for tendon or ligament injuries?

Core stack with BPC-157 injected locally. This is the strongest preclinical case: BPC-157 promotes tendon repair cell outgrowth,¹³ TB-4 increases collagen fibril diameter and fiber organization in Achilles tendon models.¹⁴ [GHK-Cu](/content/ghk-cu-skin) joins it when tissue feels unstable or re-injury keeps landing at the same site. Collagen peptides supplemented 30–45 minutes before tendon-loading exercise are a well-supported adjunct.¹⁵

### What about joint and cartilage injuries?

Joint capsule, ligament, and soft-tissue irritation can use the soft-tissue ladder. Focal cartilage defects are different: cartilage is avascular, slow, and matrix-limited. Those cases route toward a cartilage-specific stack; intra-articular BPC-157 is clinician-only at 4 mg as a single administration, not an at-home conversion. The knee case series identified 17 patients and analysed 16, reporting 87.5% overall improvement and 91.6% for BPC-157 alone, with 7 of 12 (58%) durable beyond six months.⁷

GH secretagogues can cause mild joint swelling — a reason for closer monitoring where they sit alongside a joint injury, with worsening impingement or stiffness the signal to stop. Ligament-driven injuries tolerate them better than cartilage or joint surface problems.

### Which protocol components are used for shoulder or rotator cuff injuries?

Core stack. BPC-157 produced total functional recovery in a rat rotator cuff model.¹⁷

GH secretagogues are the cautious part here. The only human RCT testing GH on rotator cuff repair (n=76) found no significant improvement, and a separate preclinical study found GH worsened tendon-bone interface strength.¹⁸ Where they're run for general recovery support, increased shoulder stiffness or swelling is the signal to watch.

### Which protocol components are used for disc, spine, or back pain?

Ordinary back strain, fascia, or capsule irritation runs on the soft-tissue ladder. Disc, nerve, and CNS presentations route differently. For disc degeneration, [VIP](/content/vasoactive-intestinal-peptide) is the only peptide with direct disc data.⁹ For nerve pain from compression, the protocol adds [ARA-290](/content/ara-290).¹⁰ BPC-157 has animal spinal-cord-injury data, but that does not make the soft-tissue stack a CNS protocol.¹⁹

No human RCTs exist for peptides in disc herniation or back pain. The evidence gap between animal spinal cord data and human disc pathology is real.

### What about post-surgical recovery?

Core stack, started 48–72 hours post-op. BPC-157 is injected near the surgical site at a flat 250–500 mcg daily across a 4–6 week course, with no loading or maintenance step and no extension for complex surgeries.¹¹

BPC-157 can counteract corticosteroid-impaired healing in preclinical models — relevant where a post-surgical protocol includes steroids.¹

### What about chronic or old injuries?

Core stack plus [GHK-Cu](/content/ghk-cu-skin) or [KPV](/content/kpv) when the bottleneck calls for it, with adjusted expectations. The BPC-157 and TB-500 course still runs 4–6 weeks before stopping to assess rather than extending for a chronic presentation. Chronic injuries have established scar tissue, adapted blood supply patterns, and often mitochondrial depletion.

[SS-31](/content/ss-31) joins when the core stack produces initial improvement that plateaus. These injuries also respond more to progressive mechanical loading — the tissue remodels along lines of mechanical stress, and progressive loading provides those stress signals.

---

## References

¹ Vasireddi N et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS J. 2025 Jul. [PMC12313605](https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/)

² Sosne G et al. "Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts." FASEB J. 2010. [PubMed 20536458](https://pubmed.ncbi.nlm.nih.gov/20536458/)

³ Dalmasso G et al. "PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation." Gastroenterology. 2008. [PMC2431115](https://pmc.ncbi.nlm.nih.gov/articles/PMC2431115/) — KPV enters cells via PepT1 transporter and blocks NF-kB activation directly; anti-inflammatory without the tissue-weakening effects of corticosteroids.

⁴ Birk AV et al. "The mitochondria-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin." J Am Soc Nephrol. 2013. [PMC3752943](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752943/) — SS-31 (elamipretide) binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport and ATP production under stress.

⁵ Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." Int J Mol Sci. 2018. [PMC6073405](https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/)

⁶ Rahman OF, Lee SJ, Seeds WA. "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions." J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). [PMC12753158](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/)

⁷ Rahman OF et al. 2026 — combined administration data, GHK-Cu orthopaedic exploration, GH secretagogue evidence, and the BPC-157 knee case series. The original series identified 17 patients and analysed 16: 87.5% overall improvement, 91.6% for BPC-157 alone, 7 of 12 (58%) durable beyond six months by telephone follow-up. The "17 patients, over 90%" figure is this review's mis-citation of the original. [PMC12753158](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/)

⁸ PDA retains the identical 15-amino-acid sequence as BPC-157, enhanced with arginate salt for increased acid stability and oral bioavailability. Rahman OF et al. 2026. [PMC12753158](https://pmc.ncbi.nlm.nih.gov/articles/PMC12753158/). Also referenced in ScienceDirect "Application of peptide therapy for ligaments and tendons," 2025 (incomplete citation: no DOI or PMID available for the ScienceDirect source).

⁹ Sun et al. "Sympathetic Neurotransmitter, VIP, Delays Intervertebral Disc Degeneration via FGF18/FGFR2." 2023/2024. Note: the link below is a press summary from Advanced Science News, not the primary publication. [Press summary](https://www.advancedsciencenews.com/an-anti-inflammatory-peptide-may-hold-the-key-to-low-back-pain-relief/)

¹⁰ Heij L et al. "Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study." Mol Med. 2012. [PMC3521784](https://pmc.ncbi.nlm.nih.gov/articles/PMC3521784/) — ARA-290 activates the innate repair receptor; neuroprotective and small-fiber regenerative without erythropoietic effects.

¹¹ Field protocol convention — TB-500 pulsed milligram dosing and the BPC-157 daily signaling-pulse model. Sources: wolverinepeptidestack.com protocols; Ben Greenfield "Ultimate Peptide Power Plays." These are uncontrolled field observations, not primary research. No controlled study has compared pulsed TB-500 dosing against daily microdosing, and the phase-based loading-and-maintenance structure these sources describe is not the derived position.

¹² SS-31 attenuated LPS-induced apoptosis and pyroptosis of nucleus pulposus cells via mitochondrial ROS scavenging. ScienceDirect 2024.

¹³ Chang et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011. [PubMed 21030672](https://pubmed.ncbi.nlm.nih.gov/21030672/)

¹⁴ **TB-4 tendon organization** — Sosne G et al. 2010. Thymosin beta-4 treated Achilles tendons showed uniform fiber bundles with increased collagen fibril diameters vs controls. [PubMed 20536458](https://pubmed.ncbi.nlm.nih.gov/20536458/)

¹⁵ Kirmani BH et al. "The effects of collagen peptide supplementation on body composition, collagen synthesis, and recovery from joint injury and exercise: a systematic review." Amino Acids. 2021. [PMC8521576](https://pmc.ncbi.nlm.nih.gov/articles/PMC8521576/) — and Kvist M et al. 2025 (collagen + explosive strength RCT). [PubMed 40623147](https://pubmed.ncbi.nlm.nih.gov/40623147/)

¹⁶ Singla M, Wang YX et al. "Blocking a master regulator of aging regenerates joint cartilage in mice." Science, Nov 2025. [Stanford News](https://news.stanford.edu/stories/2025/11/joint-cartilage-aging-osteoarthritis-therapy-research)

¹⁷ Sikiric et al. "Effect of pentadecapeptide BPC 157 on rotator cuff tear injury in rat." FASEB J. 2014;28(S1):844.9. [FASEB](https://faseb.onlinelibrary.wiley.com/doi/abs/10.1096/fasebj.28.1_supplement.844.9)

¹⁸ Oh et al. "Effect of recombinant human growth hormone on rotator cuff healing after arthroscopic repair." Am J Sports Med. 2018. [PubMed 29337026](https://pubmed.ncbi.nlm.nih.gov/29337026/) — and Vaysman et al. "Pharmacologic Enhancement of Rotator Cuff Repair: A Narrative Review." [PMC9441107](https://pmc.ncbi.nlm.nih.gov/articles/PMC9441107/)

¹⁹ Jurjus et al. "BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats." J Appl Biomed. 2019. [PubMed 31266512](https://pubmed.ncbi.nlm.nih.gov/31266512/)

²⁰ **TB-4 spinal cord injury** — "Beneficial effects of thymosin beta4 on spinal cord injury in the rat." 2014. [PubMed 24937047](https://pubmed.ncbi.nlm.nih.gov/24937047/)

²¹ Cushman CJ et al. "Local and Systemic Peptide Therapies for Soft Tissue Regeneration: A Narrative Review." Yale J Biol Med. 2024;97(3):399-413. [PMC11426299](https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/)

²² McGuire FP et al. "Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing." Curr Rev Musculoskelet Med. 2025;18(12):611-619. [PMC12446177](https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/)

²³ Liao HJ, Chen HT, Chang CH. "Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration in Osteoarthritis." Cartilage. 2024. [PMC11556548](https://pmc.ncbi.nlm.nih.gov/articles/PMC11556548/)

²⁴ Rudnik-Jansen et al. "Biomolecular therapies for chronic discogenic low back pain: A narrative review." 2024. [PMC11303450](https://pmc.ncbi.nlm.nih.gov/articles/PMC11303450/)

²⁵ Wang et al. "Phase I study of recombinant human thymosin β4." Ann Transl Med. 2021. [PMC8419156](https://pmc.ncbi.nlm.nih.gov/articles/PMC8419156/)

²⁶ **Targeted versus free systemic TB-4 in cardiac repair** — Free systemic TB-4 at the same total dose as a fibrin-targeted nanoparticle formulation produced no functional improvement. This compares a targeting vehicle against no vehicle in heart tissue; it does not compare near-injury against distal subcutaneous injection, and no study in any species has run that comparison. Huang G et al. "Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles." *Int J Nanomedicine.* 2017;12:3023-3036. [PMC5396927](https://pmc.ncbi.nlm.nih.gov/articles/PMC5396927/)

²⁷ U.S. Food and Drug Administration. Forzinity integrated review: SPISC-101 healthy-adult single- and repeated-dose elamipretide pharmacokinetics, including 6 mg SubQ daily for seven days. 2025. [FDA integrated review](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2025/215244Orig1s000IntegratedR.pdf)

*This content is for educational purposes only. Peptides discussed here are investigational compounds. Consult a physician before beginning any peptide protocol, particularly if you have active cancer, autoimmune conditions, or are taking medications that affect immune function or coagulation.*